General Patient Information

Countering Weight Gain as a Result of Hormonal Therapy.

Benefits and risks accompany virtually every method of treatment. Hormonal therapy for prostate cancer is no exception. Potential risks include osteoporosis and bone fractures, cardiac effects, diabetes, depression, hot flashes and metabolic changes resulting in weight gain. (These issues are discussed on this website under “My Story”, 2009 entries of July 5th-27th, September 29th, October more »

Avodart (dutasteride) used to treat benign prostatic hyperplasia (BPH) may slow the growth of early-stage prostate cancer

A recent study presented on Feb. 17-19th  at the 2011 Genitourinary Cancers Symposium in Orlando, FL by researchers from the University Health Network in Toronto, Canada concluded that for men who are undergoing “watchful-waiting” for prostate cancer, Avodart could help control the disease and prevent the need for more aggressive treatments. “Watchful waiting,” or active-surveillance more »

Colon cancer-a side effect of hormonal therapy.

A recent study published in the November 10th issue of the Journal of the National Cancer Institute reported that prostate cancer hormone treatments may raise the risk of colorectal cancer.  Lowering the male sex hormones by treatment with gonadotropin-releasing hormone (GnRH) agonists (hormonal therapy) or surgical removal of the testicles to lower testosterone and PSA levels led more »